Table 2.

Changes in SUVmax according to response to concurrent chemoradiotherapy

	Total	Non-CR (n = 17)	CR (n = 26)	p-valuea
Primary lesion
SUVmax0, median [range]	10.8 [0.0–26.2]	16.0 [3.5–21.0]	8.85 [0.0–26.2]
SUVmax1, median [range]	2.6 [0.0–16.0]	3.6 [0.0–16.0]	2.2 [0.0–7.8]
SUVmax decrease in percentage (%), median [range]	76.3 [−2.2–100.0]	67.7 [−2.2–100.0]	79.9 [0.0–100.0]	0.283
LN lesion
SUVmax0, median [range]	7.1 [0.0–21.0]	7.4 [0.0–21.0]	6.6 [0.0–18.2]
SUVmax1, median [range]	2.0 [0.0–16.7]	3.2 [0.0–16.7]	0.7 [0.0–5.3]
SUVmax decrease in percentage (%), median [range]	76.0 [−27.5–100.0]	62.5 [−27.5–100.0]	88.8 [0.0–100.0]	0.018

SUVmax maximum standardized uptake value, CR complete response, LN lymph node

^aStudent’s t-test